CD274 and cancer: Prior clinical trials using a PDL1 inhibitor in HNSCC showed unsatisfactory response rates in an unselected population of patients with cancer, suggesting that not all patients respond well to the PDL1 inhibitor-based immunotherapy and a subset of patients are resistant to such immunotherapy (11).